SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-172496
Filing Date
2022-06-13
Accepted
2022-06-13 08:30:32
Documents
13
Period of Report
2022-06-07
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d307902d8k.htm   iXBRL 8-K 30988
  Complete submission text file 0001193125-22-172496.txt   188308

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA labp-20220607.xsd EX-101.SCH 3244
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE labp-20220607_def.xml EX-101.DEF 13820
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE labp-20220607_lab.xml EX-101.LAB 22705
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE labp-20220607_pre.xml EX-101.PRE 14678
7 EXTRACTED XBRL INSTANCE DOCUMENT d307902d8k_htm.xml XML 4953
Mailing Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060
Business Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060 540-818-2844
Landos Biopharma, Inc. (Filer) CIK: 0001785345 (see all company filings)

IRS No.: 815085535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39971 | Film No.: 221010769
SIC: 2834 Pharmaceutical Preparations